PubRank

Bernhard Landwehrmeyer

Author PubWeight™ 36.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009 3.82
2 Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004 3.73
3 Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013 3.56
4 Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2011 2.99
5 Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009 2.19
6 Transgenic rat model of Huntington's disease. Hum Mol Genet 2003 1.66
7 Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011 1.62
8 Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005 1.33
9 Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp Neurol 2008 1.17
10 Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett 2006 1.03
11 Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Res 2006 0.98
12 Association between caffeine intake and age at onset in Huntington's disease. Neurobiol Dis 2013 0.94
13 Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats. J Biol Chem 2008 0.93
14 One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology 2013 0.89
15 A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 2008 0.88
16 Caudate nucleus and insular activation during a pain suppression paradigm comparing thermal and electrical stimulation. Open Neuroimag J 2011 0.84
17 Factor analysis of behavioural symptoms in Huntington's disease. J Neurol Neurosurg Psychiatry 2010 0.84
18 Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study. Neuroimage Clin 2012 0.82
19 Rate of change in early Huntington's disease: a clinicometric analysis. Mov Disord 2011 0.79
20 What is the impact of education on Huntington's disease? Mov Disord 2011 0.79
21 Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 2007 0.79
22 Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 2011 0.79
23 The personal experience of parenting a child with juvenile Huntington's disease: perceptions across Europe. Eur J Hum Genet 2013 0.77
24 Huntington's disease: new aspects on phenotype and genotype. Parkinsonism Relat Disord 2012 0.77
25 Graded cutaneous electrical vs thermal stimulation in humans shows different insular and cingulate cortex activation. Somatosens Mot Res 2010 0.77
26 Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes. Mov Disord 2010 0.76
27 Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment? Mov Disord 2014 0.76